Researchers of the Biotechnology and Genetics Engineering Center (CIGB in Spanish) developed a new medicine for the treatment of different neurological diseases called CIGB 845. It is the result of the pharmacological combination between a protein (epidermal growth factor) and a synthetic peptide of six aminoacids, with neuroprotective and neuro- restorative properties.

According to Bio CubaFarma Group the product can become a leading medicine in its type taking into account that there is no neuroprotective medicines effectively evaluated in the clinic and that candidates submitted to evaluation have been designed to target only one element in the cascade of physiopathology of ischemia, in contrast to CIGB 845, which targets multiple nodes of the complex pathophysiology of stroke.

The neuroprotective effect of the combination is shown in a reduction in the in the neurological deterioration, mortality and the volume of the area infarction, as clinical and non-clinical results show in phase I-II trials carried out in patients with an acute cerebral infarction of ischemic etiology.

 An improvement in the quality of life and a decrease of mortality could also be seen as well. 

Today they are working on the data provided for their statistical analysis and final report. 

In relation to intellectual property the peptide CIGB 845 has a patent granted in Canadá, China, Japón, Corea del Sur, Rusia, México, Brasil, Sudáfrica, as well as in European countries.

Source: Granma

Another achievements of the Cuba Science

Jusvinza will make the treatment of    rheumatoid arthritis and hyper inflammation possible.

https://www.lahabana.gob.cu/post_detalles/es/12925/jusvinza-permitira-tratar-la-artritis-reumatoide-y-la-hiperinflamacion